contact | help | sitemap

    en fr

 
 
 

 

 

 

Novartis Products

Novartis Products

Pharmaceuticals

Over the past decade, Novartis Pharmaceuticals Canada has introduced 20 new medicines that have had an important impact on patients suffering from a wide variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation and osteoporosis.

A C D E F G I J L M N O P R S T U V X Z

 

 

Cafergot* (discontinued) (ergotamine tartrate and caffeine)
Migraine Therapy

*Cafergot is a registered trademark

 

 

Clozaril* (clozapine)
Antipsychotic Agent

*Clozaril is a registered trademark

 

 

Comtan* (entacapone)
COMT-Inhibitor

*Comtan is a registered trademark

Research

Research

Novartis is one of the industry’s biggest investors in research.

Gilenya* (Fingolimod)

This information is intended for Canadian healthcare professionals only

ABOUT NOVARTIS

On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis

Sandoz

Sandoz

Sandoz is one of the leaders in the development, manufacturing and distribution of generic pharmaceutical products.